Erenumab-aooe is a human monoclonal antibody approved by FDA in May 2018 to use as a subcutaneous injection for the preventive treatment of migraine in adults.
Erenumab-aooe injection is prescribed to prevent migraine headaches in adult patients.
Erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that works by specifically blocking the calcitonin gene-related peptide receptor (CGRP) which is responsible for causing a migraine.
Erenumab-aooe should not be used in patients with-
• Allergy to erenumab-aooe
• Children under 18 years of age
Caution is required in treating-
• Pregnant and breastfeeding women
• Elderly patients
• The recommended adult dose is 70 mg taken once a month.
• In some specific cases, patients may be prescribed 140 mg which can be taken in two divided doses of 70 mg in a month.
• If a dose is missed, it should be taken as early as possible and the next schedule will be after a month from the date of the last dose.
• Erenumab-aooe injection comes as a single-dose prefilled syringe or prefilled autoinjector and should be administered subcutaneously or just under the skin.
• Erenumab-aooe injection should be administered into the thigh, upper arm or abdomen.
• The injection should be removed from the refrigerator and allowed to come to room temperature by keeping it out of the cold storage for at least 30 minutes.
• Do not bring the injection to room temperature by keeping it in sunlight or by using some other source of heat such as a microwave oven or hot water.
• Never shake the prefilled syringe or the autoinjector containing the injection as it may result in foaming.
• Before injecting, check the contents of the injection to ensure whether it is clear and free from particulate matter. If discoloration or any particulate matter is seen, discard the injection immediately.
• Patients should be advised to use new injection sites each time for injecting erenumab-aooe as it is always recommended to rotate the sites.
• The autoinjector and the prefilled syringe contain caps made of dry rubber which may cause some allergic reactions in patients who are allergic to dry rubber or latex.
• Patients must be trained accordingly by a healthcare provider about the handling and usage of erenumab-aooe injection before self-injecting at home.
• Never inject into scars, moles, and areas where there is tender, red, bruised, hard or scaly skin.
• Patients are advised to consult the physician immediately if any unwanted side effects or life-threatening conditions occur.
The most common side effects of erenumab-aooe include-
• Muscle pain
• Injection site reactions such as pain, swelling or redness
• Do not recommend to other people who suffer from a migraine or never take this injection for the reason it is not prescribed.
• Erenumab-aooe injection is intended for single use only.
• Not known.
• However, patients must inform the prescriber about the intake of any prescription drugs, over-the-counter medicines or herbal supplements to avoid unexpected effects with erenumab-aooe.
• Store erenumab-aooe injection in a refrigerator at 2°C to 8°C.
• Protect erenumab-aooe injection from light by placing it in its original package.
• Do not freeze or shake.
• Erenumab-aooe injection can be stored at room temperature between 20°C and 25°C for a week after removing from the refrigerator but should be discarded after a week if not used thereafter.
Subscribe to our Free Newsletters!